Kyndryl Holdings dropped 10.7% on May 6 after a Q4 earnings print that exposed a deep gap between the company's top-line progress and its bottom-line delivery — and options traders had been signalling exactly that risk.
The defensive positioning ahead of the print was unmistakable. The put/call ratio climbed to 1.35 — nearly at its 52-week high and almost 1.7 standard deviations above its 20-day average of 0.90. Investors were paying up for downside protection, and it paid off. Q4 adjusted EPS came in at $0.18, missing the $0.45 consensus by $0.27. Revenue of $3.77B edged past the $3.75B estimate. The result: a near-11% one-day drop, extending a week already down more than 6%.
Short sellers had been quietly building exposure into the event. Short interest climbed 17% over the past month to nearly 9.7% of the free float — a meaningful position, representing about 22.2 million shares. The move was steady rather than panicked, with most of the increase concentrated between early April and late April. Despite the growing short book, borrow conditions remained relaxed. Cost to borrow is below 0.5% and availability is ample, meaning the short thesis was not a crowded or costly one — bears had room to add without squeezing each other out.
The analyst community was already re-rating the story before the print. Morgan Stanley cut its target from $28 to $13 in late March. Two new initiations in April — Scotiabank at $16.50 and BMO at $15 — landed at prices already above where the stock now trades post-drop at $13.12. The mean analyst target of $14.70 implies modest recovery potential from current levels, but the consensus is firmly "hold" with five analysts at that rating and no buys in the current mix. The bull case rests on AI-driven infrastructure demand and Kyndryl's self-help transformation narrative. Bears point to management departures, disclosed internal control weaknesses, heavy US revenue concentration, and — now — a glaring EPS miss against a backdrop where the company's own FY27 sales guidance of $14.76B–$15.06B straddled the $14.97B estimate without inspiring confidence.
The EV/EBITDA multiple of 2.1x is genuinely cheap, and the PE of 6.1x reflects a market that has persistently discounted the stock's ability to convert revenue into earnings. That discount just got a fresh justification. The May 8 follow-on event will test whether management can offer a credible path to the EPS recovery the Street had priced in — and whether the structural improvement story survives another quarter of bottom-line disappointment.
See the live data behind this article on ORTEX.
Open KD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
